BB Biotech AG (BBZA.DE)
EUR 39.05
(0.77%)
EUR 39.05
(0.77%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 304.9 Million CHF | -16.01% |
| 2022 | 363 Million CHF | 2.25% |
| 2021 | 355 Million CHF | 463.49% |
| 2020 | 63 Million CHF | -58.0% |
| 2019 | 150 Million CHF | -18.92% |
| 2018 | 185 Million CHF | 94.74% |
| 2017 | 95 Million CHF | -53.66% |
| 2016 | 205 Million CHF | 28.13% |
| 2015 | 160 Million CHF | 433.33% |
| 2014 | 30 Million CHF | -66.67% |
| 2013 | 90 Million CHF | -33.33% |
| 2012 | 135 Million CHF | 0.0% |
| 2011 | - CHF | 0.0% |
| 2010 | - CHF | 0.0% |
| 2009 | - CHF | 0.0% |
| 2008 | - CHF | 0.0% |
| 2007 | - CHF | 0.0% |
| 2006 | - CHF | 0.0% |
| 2005 | - CHF | 0.0% |
| 2004 | - CHF | 0.0% |
| 2003 | - CHF | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 319.4 Million CHF | 0.0% |
| 2024 Q1 | 344.7 Million CHF | 0.0% |
| 2023 Q3 | 302.1 Million CHF | -2.07% |
| 2023 Q4 | 304.9 Million CHF | 0.93% |
| 2023 FY | 304.9 Million CHF | -16.01% |
| 2023 Q2 | 308.5 Million CHF | -2.22% |
| 2023 Q1 | 315.5 Million CHF | -13.09% |
| 2022 Q1 | 355 Million CHF | 0.0% |
| 2022 Q2 | 326 Million CHF | -8.17% |
| 2022 Q3 | - CHF | -100.0% |
| 2022 Q4 | 363 Million CHF | 0.0% |
| 2022 FY | 363 Million CHF | 2.25% |
| 2021 Q2 | - CHF | 0.0% |
| 2021 Q4 | - CHF | 0.0% |
| 2021 Q3 | - CHF | 0.0% |
| 2021 Q1 | - CHF | 0.0% |
| 2021 FY | 355 Million CHF | 463.49% |
| 2020 Q2 | - CHF | 0.0% |
| 2020 Q1 | - CHF | 0.0% |
| 2020 Q3 | - CHF | 0.0% |
| 2020 Q4 | - CHF | 0.0% |
| 2020 FY | 63 Million CHF | -58.0% |
| 2019 Q2 | - CHF | 0.0% |
| 2019 Q1 | - CHF | 0.0% |
| 2019 FY | 150 Million CHF | -18.92% |
| 2019 Q4 | - CHF | 0.0% |
| 2018 Q3 | - CHF | 0.0% |
| 2018 FY | 185 Million CHF | 94.74% |
| 2018 Q2 | - CHF | 0.0% |
| 2018 Q1 | - CHF | 0.0% |
| 2018 Q4 | - CHF | 0.0% |
| 2017 Q2 | - CHF | -100.0% |
| 2017 Q1 | 310 Million CHF | 51.22% |
| 2017 FY | 95 Million CHF | -53.66% |
| 2017 Q4 | - CHF | 0.0% |
| 2017 Q3 | - CHF | 0.0% |
| 2016 FY | 205 Million CHF | 28.13% |
| 2016 Q3 | 225 Million CHF | -34.78% |
| 2016 Q1 | 350 Million CHF | 118.75% |
| 2016 Q2 | 345 Million CHF | -1.43% |
| 2016 Q4 | 205 Million CHF | -8.89% |
| 2015 Q3 | 60 Million CHF | 0.0% |
| 2015 Q4 | 160 Million CHF | 166.67% |
| 2015 FY | 160 Million CHF | 433.33% |
| 2015 Q1 | 30 Million CHF | 0.0% |
| 2015 Q2 | - CHF | -100.0% |
| 2014 Q3 | 155 Million CHF | -11.43% |
| 2014 FY | 30 Million CHF | -66.67% |
| 2014 Q4 | 30 Million CHF | -80.65% |
| 2014 Q2 | 175 Million CHF | 7.36% |
| 2014 Q1 | 163 Million CHF | 81.11% |
| 2013 Q4 | 90 Million CHF | -28.0% |
| 2013 FY | 90 Million CHF | -33.33% |
| 2013 Q1 | 135 Million CHF | 0.0% |
| 2013 Q3 | 125 Million CHF | 27.55% |
| 2013 Q2 | 98 Million CHF | -27.41% |
| 2012 Q4 | 135 Million CHF | 0.0% |
| 2012 FY | 135 Million CHF | 0.0% |
| 2012 Q1 | - CHF | 0.0% |
| 2012 Q2 | - CHF | 0.0% |
| 2012 Q3 | - CHF | 0.0% |
| 2011 FY | - CHF | 0.0% |
| 2011 Q2 | - CHF | 0.0% |
| 2011 Q3 | - CHF | 0.0% |
| 2011 Q4 | - CHF | 0.0% |
| 2011 Q1 | - CHF | 0.0% |
| 2010 FY | - CHF | 0.0% |
| 2010 Q2 | - CHF | 0.0% |
| 2010 Q1 | - CHF | 0.0% |
| 2010 Q4 | - CHF | 0.0% |
| 2010 Q3 | - CHF | 0.0% |
| 2009 FY | - CHF | 0.0% |
| 2009 Q4 | - CHF | 0.0% |
| 2008 FY | - CHF | 0.0% |
| 2007 FY | - CHF | 0.0% |
| 2006 FY | - CHF | 0.0% |
| 2005 FY | - CHF | 0.0% |
| 2004 FY | - CHF | 0.0% |
| 2003 FY | - CHF | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BioNTech SE | 191 Million EUR | -59.634% |
| CureVac N.V. | 36.81 Million EUR | -728.105% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 19.189% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 19.189% |
| BRAIN Biotech AG | 25.19 Million EUR | -1110.257% |
| Formycon AG | 7.81 Million EUR | -3801.472% |
| Heidelberg Pharma AG | 70.4 Thousand EUR | -432953.532% |
| Medigene AG | 2.03 Million EUR | -14875.442% |